En undersøgelse af metastaser fri overlevelse med Saruparib vs placebo tilføjet til en standard RT/ADT hos mænd med højrisiko-prostatacancer med en BRCA-mutation (EvoPAR-PR02)
13. oktober 2026 opdateret af: AstraZeneca
En randomiseret, dobbeltblind, placebokontrolleret fase III-undersøgelse af adjuvans Saruparib (AZD5305) hos patienter med BRCAM-lokaliseret højrisiko-prostatacancer, der modtager radioterapi med androgenberøvelsesbehandling (Evopar-Prostate02).
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).
Studieoversigt
Status
Rekruttering
Betingelser
Detaljeret beskrivelse
Approximately, 700 adult participants with localised/locally advanced prostate cancer will be randomized in a 1:1 ratio to receive saruparib or placebo with ADT (+ abiraterone) in one of the following two cohorts:
Cohort A: 400 adult participants with newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer who have received primary RT and are receiving continuous ADT, and participants with high-risk biochemical recurrence (BCR) [including prostate-specific antigen (PSA) persistence] following a radical prostatectomy who have received salvage RT are receiving continuous ADT.
Cohort B: 300 adult participants with newly diagnosed very high-risk (locally advanced) prostate cancer who have received primary RT and who are receiving continuous ADT and abiraterone.
All participants will be followed for survival until the end of the study. Independent data monitoring committee (DMC) composed of experts will be convened to confirm the safety and efficacy of Saruparib + ADT (+ abiraterone).
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
700
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studiesteder
-
-
-
CABA, Argentina, C1113AAE
- Rekruttering
- Research Site
-
CABA, Argentina, 1426
- Rekruttering
- Research Site
-
Ciudad de Buenos Aires, Argentina, 1181
- Ikke rekrutterer endnu
- Research Site
-
Ciudad de Buenos Aires, Argentina, 1426
- Rekruttering
- Research Site
-
Ciudad de Buenos Aires, Argentina, C1419AHL
- Rekruttering
- Research Site
-
Cuidad Autónoma de Buenos Aire, Argentina, C1426ANZ
- Rekruttering
- Research Site
-
Córdoba, Argentina, 5000
- Ikke rekrutterer endnu
- Research Site
-
Córdoba, Argentina, X5008HHW
- Rekruttering
- Research Site
-
La Plata, Argentina, 1900
- Rekruttering
- Research Site
-
Pergamino, Argentina, B2700CPM
- Rekruttering
- Research Site
-
Rosario, Argentina, S2000KZE
- Rekruttering
- Research Site
-
San Miguel de Tucumán, Argentina, 4000
- Ikke rekrutterer endnu
- Research Site
-
Viedma, Argentina, R8500ACE
- Rekruttering
- Research Site
-
-
-
-
-
Kingswood, Australien, 2747
- Trukket tilbage
- Research Site
-
Murdoch, Australien, 6150
- Rekruttering
- Research Site
-
Orange, Australien, 2800
- Rekruttering
- Research Site
-
South Brisbane, Australien, 4101
- Rekruttering
- Research Site
-
St Leonards, Australien, 2065
- Rekruttering
- Research Site
-
Waratah, Australien, 2298
- Rekruttering
- Research Site
-
Woolloongabba, Australien, 4102
- Rekruttering
- Research Site
-
-
-
-
-
Brussels, Belgien, 1200
- Rekruttering
- Research Site
-
Brussels, Belgien, 1070
- Trukket tilbage
- Research Site
-
Ghent, Belgien, 9000
- Trukket tilbage
- Research Site
-
Jette, Belgien, 1090
- Rekruttering
- Research Site
-
Kortrijk, Belgien, 8500
- Rekruttering
- Research Site
-
Leuven, Belgien, 3000
- Trukket tilbage
- Research Site
-
Libramont-Chevigny, Belgien, 6800
- Rekruttering
- Research Site
-
Roeselare, Belgien, 8800
- Rekruttering
- Research Site
-
Wilrijk, Belgien, 2610
- Rekruttering
- Research Site
-
-
-
-
-
Barretos, Brasilien, 14784-400
- Ikke rekrutterer endnu
- Research Site
-
Cachoeiro de Itapemirim, Brasilien, 29308-014
- Rekruttering
- Research Site
-
Curitiba, Brasilien, 80810-050
- Rekruttering
- Research Site
-
Curitiba, Brasilien
- Rekruttering
- Research Site
-
Jaú, Brasilien, 17210-120
- Rekruttering
- Research Site
-
Londrina, Brasilien, 86015-520
- Rekruttering
- Research Site
-
Pelotas, Brasilien, 96020-080
- Rekruttering
- Research Site
-
Porto Alegre, Brasilien, 91350200
- Rekruttering
- Research Site
-
Porto Alegre, Brasilien, 90035-000
- Trukket tilbage
- Research Site
-
Recife, Brasilien, 50070-460
- Ikke rekrutterer endnu
- Research Site
-
Rio de Janeiro, Brasilien, 22775-001
- Rekruttering
- Research Site
-
Rio de Janeiro, Brasilien, 22.250-905
- Rekruttering
- Research Site
-
Salvador, Brasilien, 41950640
- Rekruttering
- Research Site
-
São Paulo, Brasilien, 01246-000
- Rekruttering
- Research Site
-
São Paulo, Brasilien, 01327-001
- Rekruttering
- Research Site
-
-
-
-
-
Toronto, Canada, M4N 3M5
- Trukket tilbage
- Research Site
-
-
Alberta
-
Calgary, Alberta, Canada, T2V 1P9
- Trukket tilbage
- Research Site
-
-
British Columbia
-
Abbotsford British Columbia, British Columbia, Canada, V2S 0C2
- Trukket tilbage
- Research Site
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Trukket tilbage
- Research Site
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Trukket tilbage
- Research Site
-
Brampton, Ontario, Canada, L6R 3J7
- Trukket tilbage
- Research Site
-
London, Ontario, Canada, N6A 5A5
- Trukket tilbage
- Research Site
-
Toronto, Ontario, Canada, M5G 2M9
- Trukket tilbage
- Research Site
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 7K9
- Trukket tilbage
- Research Site
-
Montreal, Quebec, Canada, H3T 1E2
- Trukket tilbage
- Research Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Trukket tilbage
- Research Site
-
-
-
-
-
Concepción, Chile, 4070196
- Trukket tilbage
- Research Site
-
La Serena, Chile, 1720430
- Trukket tilbage
- Research Site
-
Temuco, Chile, 4781156
- Trukket tilbage
- Research Site
-
-
-
-
-
Aberdeen, Det Forenede Kongerige, AB25 2ZN
- Rekruttering
- Research Site
-
Bristol, Det Forenede Kongerige, BS2 8ED
- Rekruttering
- Research Site
-
Cambridge, Det Forenede Kongerige, CB2 0QQ
- Rekruttering
- Research Site
-
Edinburgh, Det Forenede Kongerige, EH4 2XU
- Rekruttering
- Research Site
-
Exeter, Det Forenede Kongerige, EX2 5DW
- Rekruttering
- Research Site
-
Glasgow, Det Forenede Kongerige, G12 0YN
- Rekruttering
- Research Site
-
Greater London, Det Forenede Kongerige, SW3 6JJ
- Rekruttering
- Research Site
-
Guildford, Det Forenede Kongerige, GU2 7XX
- Rekruttering
- Research Site
-
London, Det Forenede Kongerige, NW3 2QG
- Rekruttering
- Research Site
-
London, Det Forenede Kongerige, WC1N 3BG
- Rekruttering
- Research Site
-
London, Det Forenede Kongerige, EC1M6BQ
- Trukket tilbage
- Research Site
-
Manchester, Det Forenede Kongerige, M20 4BX
- Rekruttering
- Research Site
-
Newcastle, Det Forenede Kongerige, NE7 7DN
- Trukket tilbage
- Research Site
-
Plymouth, Det Forenede Kongerige, PL6 8DH
- Rekruttering
- Research Site
-
Preston, Det Forenede Kongerige, PR2 9HT
- Trukket tilbage
- Research Site
-
Romford, Det Forenede Kongerige, RM7 0AG
- Rekruttering
- Research Site
-
-
-
-
-
Helsinki, Finland, 00290
- Rekruttering
- Research Site
-
Helsinki, Finland, FI-00180
- Rekruttering
- Research Site
-
Kuopio, Finland, 70210
- Rekruttering
- Research Site
-
Oulu, Finland, 90029
- Ikke rekrutterer endnu
- Research Site
-
Tampere, Finland, FI-33521
- Rekruttering
- Research Site
-
Turku, Finland, 20520
- Rekruttering
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85054
- Rekruttering
- Research Site
-
Tucson, Arizona, Forenede Stater, 85741
- Trukket tilbage
- Research Site
-
-
California
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Research Site
-
La Jolla, California, Forenede Stater, 92093
- Rekruttering
- Research Site
-
Los Angeles, California, Forenede Stater, 90048
- Rekruttering
- Research Site
-
San Diego, California, Forenede Stater, 92123
- Rekruttering
- Research Site
-
San Luis Obispo, California, Forenede Stater, 93401
- Rekruttering
- Research Site
-
-
Colorado
-
Lakewood, Colorado, Forenede Stater, 80215
- Rekruttering
- Research Site
-
-
Florida
-
Hialeah, Florida, Forenede Stater, 33016
- Rekruttering
- Research Site
-
Jacksonville, Florida, Forenede Stater, 32224
- Rekruttering
- Research Site
-
Tallahassee, Florida, Forenede Stater, 32308
- Trukket tilbage
- Research Site
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Research Site
-
-
Georgia
-
Newnan, Georgia, Forenede Stater, 30265
- Rekruttering
- Research Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Research Site
-
Chicago Ridge, Illinois, Forenede Stater, 60415
- Rekruttering
- Research Site
-
Lake Barrington, Illinois, Forenede Stater, 60010
- Trukket tilbage
- Research Site
-
-
Indiana
-
Greenwood, Indiana, Forenede Stater, 46143
- Rekruttering
- Research Site
-
Jeffersonville, Indiana, Forenede Stater, 47130
- Trukket tilbage
- Research Site
-
-
Maryland
-
Bethesda, Maryland, Forenede Stater, 20817
- Trukket tilbage
- Research Site
-
Towson, Maryland, Forenede Stater, 21204
- Rekruttering
- Research Site
-
-
Massachusetts
-
Plymouth, Massachusetts, Forenede Stater, 02360
- Rekruttering
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Research Site
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- Research Site
-
Voorhees Township, New Jersey, Forenede Stater, 08043
- Rekruttering
- Research Site
-
-
New York
-
Albany, New York, Forenede Stater, 12206
- Trukket tilbage
- Research Site
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Research Site
-
Syracuse, New York, Forenede Stater, 13210
- Rekruttering
- Research Site
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43230
- Rekruttering
- Research Site
-
-
Oregon
-
Springfield, Oregon, Forenede Stater, 97477
- Rekruttering
- Research Site
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater, 17033
- Rekruttering
- Research Site
-
Lancaster, Pennsylvania, Forenede Stater, 17601
- Rekruttering
- Research Site
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- Rekruttering
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Rekruttering
- Research Site
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forenede Stater, 29572
- Rekruttering
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37209
- Rekruttering
- Research Site
-
-
Texas
-
Austin, Texas, Forenede Stater, 78745
- Rekruttering
- Research Site
-
Austin, Texas, Forenede Stater, 78705
- Rekruttering
- Research Site
-
Houston, Texas, Forenede Stater, 77074
- Rekruttering
- Research Site
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Research Site
-
Spring, Texas, Forenede Stater, 77380
- Rekruttering
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Trukket tilbage
- Research Site
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23502
- Rekruttering
- Research Site
-
Roanoke, Virginia, Forenede Stater, 24014
- Rekruttering
- Research Site
-
Virginia Beach, Virginia, Forenede Stater, 23462
- Rekruttering
- Research Site
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Trukket tilbage
- Research Site
-
-
-
-
-
Angers, Frankrig, 49100
- Rekruttering
- Research Site
-
Bordeaux, Frankrig, 33000
- Rekruttering
- Research Site
-
Caen, Frankrig, 14076
- Rekruttering
- Research Site
-
Clermont-Ferrand, Frankrig, 63011
- Rekruttering
- Research Site
-
Le Mans, Frankrig, 72000
- Rekruttering
- Research Site
-
Marseille, Frankrig, 13273
- Trukket tilbage
- Research Site
-
Montpellier, Frankrig, 34070
- Rekruttering
- Research Site
-
Montpellier, Frankrig, 34298
- Rekruttering
- Research Site
-
Nice, Frankrig, 06100
- Rekruttering
- Research Site
-
Nîmes, Frankrig, 30029
- Rekruttering
- Research Site
-
Paris, Frankrig, 75020
- Rekruttering
- Research Site
-
Paris, Frankrig, 75970
- Rekruttering
- Research Site
-
Paris, Frankrig, 75674
- Rekruttering
- Research Site
-
Pierre-Bénite, Frankrig, 69310
- Rekruttering
- Research Site
-
Rennes, Frankrig, 35000
- Trukket tilbage
- Research Site
-
Saint-Herblain, Frankrig, 44805
- Rekruttering
- Research Site
-
Saint-Priest-en-Jarez, Frankrig, 42270
- Rekruttering
- Research Site
-
Strasbourg, Frankrig, 67200
- Rekruttering
- Research Site
-
Suresnes, Frankrig, 92151
- Rekruttering
- Research Site
-
Tours, Frankrig, 37044
- Rekruttering
- Research Site
-
Vandœuvre-lès-Nancy, Frankrig, 54511
- Rekruttering
- Research Site
-
Villejuif, Frankrig, 94805
- Rekruttering
- Research Site
-
-
-
-
-
Hilversum, Holland, 1213 XZ
- Rekruttering
- Research Site
-
Hoofddorp, Holland, 2134 TM
- Trukket tilbage
- Research Site
-
Maastricht, Holland, 6202 AZ
- Rekruttering
- Research Site
-
Nijmegen, Holland, 6532 SZ
- Rekruttering
- Research Site
-
Roosendaal, Holland, 4708 AE
- Rekruttering
- Research Site
-
-
-
-
-
Ansārinagar, Indien, 110 029
- Rekruttering
- Research Site
-
Babgalore, Indien, 560069
- Rekruttering
- Research Site
-
Calicut, Indien, 673601
- Trukket tilbage
- Research Site
-
Delhi, Indien, 110085
- Trukket tilbage
- Research Site
-
Hyderabad, Indien, 500019
- Rekruttering
- Research Site
-
Kannur, Indien, 670103
- Rekruttering
- Research Site
-
Kanpur, Indien, 208005
- Rekruttering
- Research Site
-
Mumbai, Indien, 400012
- Rekruttering
- Research Site
-
Nagpur, Indien, 440001
- Rekruttering
- Research Site
-
Varanasi, Indien, 221005
- Rekruttering
- Research Site
-
-
-
-
-
Afula, Israel, 18101
- Rekruttering
- Research Site
-
Beersheba, Israel, 8410101
- Rekruttering
- Research Site
-
Hadera, Israel, 38100
- Ikke rekrutterer endnu
- Research Site
-
Haifa, Israel, 31096
- Rekruttering
- Research Site
-
Jerusalem, Israel, 91031
- Rekruttering
- Research Site
-
Jerusalem, Israel, 9112001
- Rekruttering
- Research Site
-
Kfar Saba, Israel, 4428164
- Rekruttering
- Research Site
-
Nahariya, Israel, 22100
- Ikke rekrutterer endnu
- Research Site
-
Petah Tikva, Israel, 49100
- Rekruttering
- Research Site
-
Ramat Gan, Israel, 52621
- Rekruttering
- Research Site
-
Tel Aviv, Israel, 6423906
- Rekruttering
- Research Site
-
-
-
-
-
Arezzo, Italien, 52100
- Rekruttering
- Research Site
-
Bari, Italien, 70124
- Rekruttering
- Research Site
-
Bergamo, Italien, 24127
- Rekruttering
- Research Site
-
Bergamo, Italien, 24125
- Rekruttering
- Research Site
-
Chieti, Italien, 66100
- Ikke rekrutterer endnu
- Research Site
-
Genoa, Italien, 16132
- Rekruttering
- Research Site
-
Milan, Italien, 20132
- Rekruttering
- Research Site
-
Milan, Italien, 20141
- Rekruttering
- Research Site
-
Milan, Italien, 20133
- Rekruttering
- Research Site
-
Naples, Italien, 80131
- Rekruttering
- Research Site
-
Palermo, Italien, 90127
- Rekruttering
- Research Site
-
Pisa, Italien, 56126
- Rekruttering
- Research Site
-
Roma, Italien, 00168
- Rekruttering
- Research Site
-
Roma, Italien, 00144
- Rekruttering
- Research Site
-
Rozzano, Italien, 20089
- Rekruttering
- Research Site
-
Torino, Italien, 10126
- Rekruttering
- Research Site
-
Varese, Italien, 21100
- Rekruttering
- Research Site
-
Verona, Italien, 37134
- Rekruttering
- Research Site
-
-
-
-
-
Bunkyō City, Japan, 113-8431
- Rekruttering
- Research Site
-
Fukuoka, Japan, 812-8582
- Rekruttering
- Research Site
-
Kamakura-shi, Japan, 247-8533
- Rekruttering
- Research Site
-
Kawagoe-shi, Japan, 350-8550
- Rekruttering
- Research Site
-
Kawasaki-shi, Japan, 216-8511
- Rekruttering
- Research Site
-
Kisarazu-shi, Japan, 292-8535
- Rekruttering
- Research Site
-
Kumamoto, Japan, 860-8556
- Rekruttering
- Research Site
-
Kyoto, Japan, 606-8507
- Ikke rekrutterer endnu
- Research Site
-
Maebashi, Japan, 371-8511
- Rekruttering
- Research Site
-
Miyazaki, Japan, 889-1692
- Rekruttering
- Research Site
-
Sagamihara-shi, Japan, 252-0375
- Rekruttering
- Research Site
-
Shimotsuke-shi, Japan, 329-0498
- Rekruttering
- Research Site
-
Yokohama, Japan, 241-8515
- Rekruttering
- Research Site
-
Yokohama, Japan, 232-0024
- Rekruttering
- Research Site
-
Ōta-ku, Japan, 373-8550
- Rekruttering
- Research Site
-
-
-
-
-
Beijing, Kina, 100020
- Rekruttering
- Research Site
-
Beijing, Kina, 100021
- Rekruttering
- Research Site
-
Beijing, Kina, 100176
- Rekruttering
- Research Site
-
Changchun, Kina, 130012
- Rekruttering
- Research Site
-
Changsha, Kina, 410013
- Rekruttering
- Research Site
-
Chongqing, Kina, 400016
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510280
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510080
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510060
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510180
- Rekruttering
- Research Site
-
Hangzhou, Kina, 310022
- Rekruttering
- Research Site
-
Hangzhou, Kina, 31000
- Ikke rekrutterer endnu
- Research Site
-
Jinan, Kina, 250021
- Rekruttering
- Research Site
-
Jinhua, Kina, 322100
- Rekruttering
- Research Site
-
Lanzhou, Kina, 730030
- Trukket tilbage
- Research Site
-
Nanchang, Kina, 330006
- Rekruttering
- Research Site
-
Ningbo, Kina, 315010
- Rekruttering
- Research Site
-
Shanghai, Kina, 200025
- Rekruttering
- Research Site
-
Shanghai, Kina, 20032
- Trukket tilbage
- Research Site
-
Shenyang, Kina, 110001
- Rekruttering
- Research Site
-
Shenyang, Kina, 110042
- Trukket tilbage
- Research Site
-
Sichuan, Kina, 610041
- Rekruttering
- Research Site
-
Suining, Kina, 629018
- Rekruttering
- Research Site
-
Tianjin, Kina, 300201
- Rekruttering
- Research Site
-
Wuhan, Kina, 430022
- Rekruttering
- Research Site
-
Wuhan, Kina, 430060
- Rekruttering
- Research Site
-
Wuhu, Kina, 241000
- Rekruttering
- Research Site
-
Xiamen, Kina, 361003
- Rekruttering
- Research Site
-
Yangzhou, Kina, 225001
- Rekruttering
- Research Site
-
Zhuhai, Kina, 519099
- Rekruttering
- Research Site
-
-
-
-
-
Batu Caves, Malaysia, 68100
- Trukket tilbage
- Research Site
-
Kuala Lumpur, Malaysia, 59100
- Trukket tilbage
- Research Site
-
Kuala Selangor, Malaysia, 62250
- Trukket tilbage
- Research Site
-
Pulau Pinang, Malaysia, 10450
- Trukket tilbage
- Research Site
-
-
-
-
-
Lima, Peru, 15036
- Trukket tilbage
- Research Site
-
Lima, Peru, LIMA 29
- Trukket tilbage
- Research Site
-
Lima, Peru, Lima 34
- Trukket tilbage
- Research Site
-
Trujillo, Peru, 13008
- Trukket tilbage
- Research Site
-
-
-
-
-
Gdynia, Polen, 81-519
- Rekruttering
- Research Site
-
Gliwice, Polen, 44-101
- Rekruttering
- Research Site
-
Koszalin, Polen, 75-581
- Rekruttering
- Research Site
-
Krakow, Polen, 30-727
- Rekruttering
- Research Site
-
Piotrkow Trybunalski, Polen, 97-300
- Rekruttering
- Research Site
-
Poznan, Polen, 61-731
- Rekruttering
- Research Site
-
Rzeszów, Polen, 35-001
- Rekruttering
- Research Site
-
Warsaw, Polen, 04-073
- Rekruttering
- Research Site
-
-
-
-
-
Barcelona, Spanien, 08041
- Rekruttering
- Research Site
-
Barcelona, Spanien, 8035
- Rekruttering
- Research Site
-
Girona, Spanien, 17007
- Rekruttering
- Research Site
-
Madrid, Spanien, 28040
- Rekruttering
- Research Site
-
Madrid, Spanien, 28041
- Rekruttering
- Research Site
-
Madrid, Spanien, 28046
- Rekruttering
- Research Site
-
Majadahonda, Spanien, 28222
- Rekruttering
- Research Site
-
Málaga, Spanien, 29010
- Rekruttering
- Research Site
-
Málaga, Spanien, 29009
- Rekruttering
- Research Site
-
Oviedo, Spanien, 33011
- Rekruttering
- Research Site
-
Sabadell, Spanien, 08208
- Rekruttering
- Research Site
-
Santander, Spanien, 39008
- Rekruttering
- Research Site
-
Valencia, Spanien, 46014
- Rekruttering
- Research Site
-
Valencia, Spanien, 46009
- Rekruttering
- Research Site
-
-
-
-
-
Gothenburg, Sverige, 413 45
- Rekruttering
- Research Site
-
Malmö, Sverige, 205 02
- Rekruttering
- Research Site
-
Stockholm, Sverige, 141 86
- Rekruttering
- Research Site
-
Stockholm, Sverige, 112 81
- Trukket tilbage
- Research Site
-
Umeå, Sverige, 901 85
- Rekruttering
- Research Site
-
Uppsala, Sverige, 75185
- Rekruttering
- Research Site
-
-
-
-
-
Busan, Sydkorea, 49241
- Rekruttering
- Research Site
-
Daegu, Sydkorea, 41404
- Rekruttering
- Research Site
-
Goyang-si, Sydkorea, 10408
- Rekruttering
- Research Site
-
Seongnam-si, Sydkorea, 13620
- Trukket tilbage
- Research Site
-
Seoul, Sydkorea, 03080
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 06351
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 5505
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 06591
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 3722
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 06273
- Rekruttering
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Rekruttering
- Research Site
-
Taichung, Taiwan, 40705
- Rekruttering
- Research Site
-
Taichung, Taiwan, 43503
- Rekruttering
- Research Site
-
Tainan, Taiwan, 704
- Rekruttering
- Research Site
-
Taipei, Taiwan, 112
- Rekruttering
- Research Site
-
Taipei, Taiwan, 110
- Rekruttering
- Research Site
-
Taipei, Taiwan, 10055
- Rekruttering
- Research Site
-
Taoyuan, Taiwan, 333
- Rekruttering
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10210
- Rekruttering
- Research Site
-
Bangkok, Thailand, 10400
- Rekruttering
- Research Site
-
Bangkok, Thailand, 10700
- Rekruttering
- Research Site
-
Khon Kaen, Thailand, 40002
- Rekruttering
- Research Site
-
Muang, Thailand, 50200
- Rekruttering
- Research Site
-
Pathum Thani, Thailand, 12120
- Rekruttering
- Research Site
-
Songkhla, Thailand, 90110
- Rekruttering
- Research Site
-
-
-
-
-
Ankara, Tyrkiet (Türkiye), 06800
- Rekruttering
- Research Site
-
Ankara, Tyrkiet (Türkiye), 06620
- Rekruttering
- Research Site
-
Ankara, Tyrkiet (Türkiye), 06010
- Rekruttering
- Research Site
-
Ankara, Tyrkiet (Türkiye), 06520
- Rekruttering
- Research Site
-
Cordaleo, Tyrkiet (Türkiye), 35575
- Rekruttering
- Research Site
-
Diyarbakır, Tyrkiet (Türkiye), 21280
- Rekruttering
- Research Site
-
Istanbul, Tyrkiet (Türkiye), 34722
- Rekruttering
- Research Site
-
Istanbul, Tyrkiet (Türkiye), 34098
- Rekruttering
- Research Site
-
Istanbul, Tyrkiet (Türkiye), 34010
- Rekruttering
- Research Site
-
Izmir, Tyrkiet (Türkiye), 35040
- Rekruttering
- Research Site
-
Sakarya, Tyrkiet (Türkiye), 54290
- Rekruttering
- Research Site
-
Seyhan, Tyrkiet (Türkiye), 01130
- Trukket tilbage
- Research Site
-
Şahinbey, Tyrkiet (Türkiye), 27310
- Rekruttering
- Research Site
-
-
-
-
-
Augsburg, Tyskland, 86156
- Rekruttering
- Research Site
-
Berlin, Tyskland, 10117
- Rekruttering
- Research Site
-
Braunschweig, Tyskland, 38126
- Rekruttering
- Research Site
-
Cologne, Tyskland, 50937
- Rekruttering
- Research Site
-
Dresden, Tyskland, 1307
- Rekruttering
- Research Site
-
Duisburg, Tyskland, 47169
- Rekruttering
- Research Site
-
Düsseldorf, Tyskland, 40226
- Rekruttering
- Research Site
-
Essen, Tyskland, 45147
- Rekruttering
- Research Site
-
Giessen, Tyskland, 35392
- Rekruttering
- Research Site
-
Gronau, Tyskland, 48599
- Ikke rekrutterer endnu
- Research Site
-
Göttingen, Tyskland, 37075
- Rekruttering
- Research Site
-
Hamburg, Tyskland, 20246
- Rekruttering
- Research Site
-
Herne, Tyskland, 44625
- Rekruttering
- Research Site
-
Kiel, Tyskland, 24105
- Trukket tilbage
- Research Site
-
Lübeck, Tyskland, 23538
- Rekruttering
- Research Site
-
Marburg, Tyskland, 35043
- Rekruttering
- Research Site
-
Münster, Tyskland, 48149
- Rekruttering
- Research Site
-
Nuremberg, Tyskland, 90419
- Rekruttering
- Research Site
-
Nürtingen, Tyskland, 72622
- Rekruttering
- Research Site
-
Regensburg, Tyskland, 93053
- Rekruttering
- Research Site
-
Schwerin, Tyskland, 19049
- Rekruttering
- Research Site
-
Trier, Tyskland, 54292
- Rekruttering
- Research Site
-
Ulm, Tyskland, 89081
- Rekruttering
- Research Site
-
Würzburg, Tyskland, 97080
- Rekruttering
- Research Site
-
-
-
-
-
Budapest, Ungarn, 1122
- Rekruttering
- Research Site
-
Budapest, Ungarn, 1082
- Rekruttering
- Research Site
-
Budapest, Ungarn, H-1145
- Trukket tilbage
- Research Site
-
Debrecen, Ungarn, 4032
- Rekruttering
- Research Site
-
Gyula, Ungarn, 5700
- Rekruttering
- Research Site
-
Győr, Ungarn, 9024
- Rekruttering
- Research Site
-
Zalaegerszeg, Ungarn, 8900
- Rekruttering
- Research Site
-
-
-
-
-
Graz, Østrig, 8036
- Rekruttering
- Research Site
-
Innsbruck, Østrig, 6020
- Rekruttering
- Research Site
-
Linz, Østrig, 4020
- Rekruttering
- Research Site
-
Vienna, Østrig, 1090
- Ikke rekrutterer endnu
- Research Site
-
Vienna, Østrig, 1020
- Rekruttering
- Research Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Han
Beskrivelse
Inclusion Criteria:
- Male participants with a histologically documented diagnosis of prostate adenocarcinoma.
- Newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer or a high-risk biochemical recurrence (BCR) following radical prostatectomy.
- Provision of a formalin fixed and paraffin embedded (FFPE) tumour tissue sample.
- Confirmed BRCA1 or BRCA2 mutation status by central tumour tissue is required for enrolment.
- Participants required to have a computed tomography (CT) or magnetic resonance imaging (MRI) and a bone scan following the completion of their planned RT. This screening scan must confirm no evidence of disease or evidence of disease confined to the pelvis (M0).
- Participants required to have a prostate-specific membrane antigen-positron emission tomography (PSMA-PET) following the completion of their planned RT. This screening scan must confirm no evidence of disease or evidence of disease confined to the pelvis (M0).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomization.
- Minimum life expectancy of 12 months.
- Adequate organ and bone marrow function as described in study protocol.
- All participants will have received either primary or salvage RT. Participants must be eligible for randomisation within 10 months of initial diagnosis (de novo or BCR). Radiotherapy administered to the prostate (± pelvis) either in the primary or salvage setting must be delivered with curative intent. Use of metastases-directed therapy, as part of the RT radiation plan, is permitted as localised RT treatment for a metastatic lesion(s) outside the pelvis.
- All participants will have received a planned regimen of ADT with a gonadotropin releasing hormone (GnRH) analogue.
- Participants must not father children or donate sperm from signing informed consent form (ICF), during the study intervention and for 6 months after the last dose of study intervention.
- Participants must use a condom (with spermicide - where permitted) from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners.
Exclusion Criteria:
- Participants with a history of myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
- Participants with any known predisposition to bleeding [e.g., active peptic ulceration, recent (within 6 months) hemorrhagic stroke, proliferative diabetic retinopathy].
- Any history of persisting (> 2 weeks) severe cytopenia due to any cause.
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of saruparib and/or abiraterone.
- History of another primary malignancy, with exceptions.
- Persistent toxicities [Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2] caused by previous anticancer therapy.
- Cardiac criteria, including history of arrhythmia and cardiovascular disease.
- Evidence of active and uncontrolled hepatitis B and/or hepatitis C.
- Evidence of active and uncontrolled human immunodeficiency virus (HIV) infection.
- Active tuberculosis infection.
- Any prior chemotherapy (i.e., docetaxel) or immunotherapy; any prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor.
- Prior treatment within 14 days with blood product support or growth factor support.
- Concomitant use of strong inducers and inhibitors of CYP3A4 (applies to saruparib and abiraterone) or herbal supplements within 21 days or at least 5 half-lives (whichever is longer), of randomization.
- Concomitant use of drugs that are known to prolong QT and have a known risk of Torsades de Pointes (TdP).
- Participants with a known hypersensitivity to saruparib or any excipients of these products.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Cohort A: Saruparib (AZD5305) + Physician's Choice ADT
Participants will receive saruparib along with ADT. |
Saruparib will be administered orally.
Andre navne:
Standard of care ADT will be administered. |
|
Placebo komparator: Cohort A: Placebo + Physician's Choice ADT
Participants will receive matching placebo to saruparib along with ADT. |
Standard of care ADT will be administered. Matching placebo to saruparib will be administered orally. |
|
Eksperimentel: Cohort B: Saruparib (AZD5305) + Physician's Choice ADT + Abiraterone (and prednisone/prednisolone)
Participants will receive saruparib, abiraterone and prednisolone/prednisone along with ADT. |
Saruparib will be administered orally.
Andre navne:
Standard of care ADT will be administered. Abiraterone will be administered orally in combination with prednisone/prednisolone. |
|
Placebo komparator: Cohort B: Placebo + Physician's Choice ADT + Abiraterone (and prednisone/prednisolone)
Participants will receive matching placebo to saruparib, abiraterone and prednisolone/prednisone along with ADT. |
Standard of care ADT will be administered. Matching placebo to saruparib will be administered orally. Abiraterone will be administered orally in combination with prednisone/prednisolone. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Metastasis-free survival (MFS)
Tidsramme: Up to approximately 93 months
|
MFS is defined as the time from randomisation until the date of first appearance of distant metastases, confirmed by standard clinical imaging [computed tomography (CT)/ magnetic resonance imaging (MRI) and bone scan, or prostate-specific membrane antigen-positron emission tomography (PSMA-PET)], as assessed by blinded independent central review (BICR) or death due to any cause. |
Up to approximately 93 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival (OS)
Tidsramme: Up to approximately 11 years
|
OS is defined as the time from randomisation until the date of death due to any cause. |
Up to approximately 11 years
|
|
MFS (CT/MRI and bone scan)
Tidsramme: Up to approximately 93 months
|
MFS is defined as the time from randomisation until the date of distant metastases, confirmed by conventional imaging (CT/MRI and bone scan), or death due to any cause. |
Up to approximately 93 months
|
|
MFS (PSMA-PET)
Tidsramme: Up to approximately 93 months
|
MFS is defined as the time from randomisation until the date of distant metastases, confirmed by PSMA-PET imaging or death due to any cause. |
Up to approximately 93 months
|
|
MFS (standard clinical imaging)
Tidsramme: Up to approximately 93 months
|
MFS is defined as the time from randomisation until the date of distant metastases, confirmed by standard clinical imaging (CT/MRI and bone scan or PSMA-PET), histology, or death due to any cause. |
Up to approximately 93 months
|
|
Time from randomisation to Progression Free Survival 2 (PFS2)
Tidsramme: Up to approximately 93 months
|
Time from randomisation to PFS2 is defined as the time from randomisation to the earliest of progression [defined as radiographic progression, clinical progression, or prostate-specific antigen (PSA) progression] after initiation of first subsequent systemic treatment following the initial investigator-assessed progression or death. The date of second progression will be investigator assessed according to local standard clinical practice. |
Up to approximately 93 months
|
|
Time to biochemical recurrence
Tidsramme: Up to approximately 93 months
|
Time to biochemical recurrence is defined as the time from randomisation to biochemical recurrence per Phoenix criteria. |
Up to approximately 93 months
|
|
Prostate cancer-specific survival (PCSS)
Tidsramme: Up to approximately 11 years
|
PCSS is defined as the time from randomisation until the date of death due to the underlying prostate cancer. |
Up to approximately 11 years
|
|
Time to deterioration in urinary symptoms (TTDUS)
Tidsramme: Up to approximately 93 months
|
TTDUS is defined as the time from randomisation to deterioration in EORTC-QLQ-PR25 (US) subscale scores. |
Up to approximately 93 months
|
|
Time to deterioration in physical function (TTDPF)
Tidsramme: Up to approximately 93 months
|
TTDPF is defined as the time from randomisation to deterioration in EORTC-QLQ-C30 Physical Function subscale scores. |
Up to approximately 93 months
|
|
Plasma concentrations of saruparib
Tidsramme: Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety). |
Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
|
Area under the curve (AUC)
Tidsramme: Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety). |
Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
|
Maximum observed concentration (Cmax)
Tidsramme: Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety). |
Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
|
Time to Cmax (Tmax)
Tidsramme: Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety). |
Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
|
Number of participants with adverse events (AEs)
Tidsramme: Up to approximately 11 years
|
To assess the safety and tolerability of saruparib administered in combination with ADT alone (Cohort A) and in combination with ADT + abiraterone (Cohort B). |
Up to approximately 11 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
6. august 2025
Primær færdiggørelse (Anslået)
31. marts 2033
Studieafslutning (Anslået)
30. april 2036
Datoer for studieregistrering
Først indsendt
30. april 2025
Først indsendt, der opfyldte QC-kriterier
30. april 2025
Først opslået (Faktiske)
1. maj 2025
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
14. oktober 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
13. oktober 2026
Sidst verificeret
1. oktober 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Genitale neoplasmer, mandlige
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Kønssygdomme, mandlige
- Prostatasygdomme
- Mandlige urogenitale sygdomme
- Prostatiske neoplasmer
- Lægemidlers fysiologiske virkninger
- Hormoner, hormonsubstitutter og hormonantagonister
- Hormonantagonister
- Farmakologiske handlinger
- Kemiske handlinger og anvendelser
- Polycykliske forbindelser
- Gravidier
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Gravideretrioler
- Gravideretioler
- Prednison
- Prednisolon
- Androgenantagonister
- Abiraterone
- AZD5305
Andre undersøgelses-id-numre
- D9727C00001
- 2024-513586-39 (Anden identifikator: EU CT Number)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delingsadgangskriterier
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ja
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .